Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure

Effect of 4 Weeks Treatment With Acipimox on Left Ventricular Function, Work Capacity, Insulin Sensitivity and Substrate Metabolism in Patients With Chronic Heart Failure

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00549614

Acronym

ACME

Enrollment

Registered

2007-10-26

Start date

2007-10-31

Completion date

2009-05-31

Last updated

2009-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

heart failure

Brief summary

The primary objective of this study is to evaluate whether metabolic modulation improves left ventricular function, work capacity, insulin sensitivity and modifies substrate metabolism in chronic heart failure

Interventions

DRUGacipimox

capsule, 250 mg, 4 times daily for 28 days

DRUGplacebo

capsule, 250 mg, 4 times daily for 28 days

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Inclusion criteria

* EF\<40 % * IHD * NYHA-class II-III.

Exclusion criteria

* pregnancy * severe renal failure * new brady- or tachyArrhythmia * Severe stenotic valvular disease * myocardial infarction within last 6 weeks * insulin treated diabetes mellitus * peptic ulcer * pregnancy or lactating women * allergy towards tested medicine

Design outcomes

Primary

Measure	Time frame
left ventricular ejection Fraction	4 weeks
exercise capacity	4 weeks
muscular metabolism	4 weeks

Secondary

Measure	Time frame
regional left ventricular function	4 weeks
insulin resistance	4 weeks
full body metabolism	4 weeks

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026